Tata India Pharma & Healthcare Fund
Tata India Pharma & Healthcare Fund portfolio holdings, Oct 2026: 40 stocks, ₹1,495 cr in listed equity, from Tata Mutual Fund's monthly disclosure; changes by share count against Sep 2026.
Fund managers: Rajat Srivastava
Benchmark: BSE Healthcare TRI · Riskometer: Very High · SEBI category, as filed: Sectoral Fund · Allotted 28 Dec 2015
Source: AMFI scheme summary document
Tata India Pharma & Healthcare Fund - Direct Plan - Growth Option
Source: AMFI
The scheme's yearly running cost as a % of its assets, taken out of the NAV a little each day. A regular plan costs more: it pays a distributor's commission.
Category median: direct 1.23 %, regular 2.40 % (174 schemes) · Regular costs ₹1,310 more a year per ₹1 lakh
Of this, the base expense ratio, the part SEBI caps: direct 0.62 %, regular 1.79 %. The rest is brokerage, transaction costs and statutory levies such as GST and STT, as AMFI's file lists them.
A year, as of 21 Nov 2026. Source: AMFI · Glossary: TER
40 stocks, Oct 2026.
As the AMC's file prints % of NAV. The top 10 stocks together: 50.1%.
This month: Oct 2026
compared with Sep 2026 · by share countMoves, Oct 2026
How many stocks the scheme bought into, added to, cut or sold out of this month, by share count, so a price move alone never counts.
- New1
- Added12
- Trimmed7
- Exited3
Asset mix, Oct 2026
How much of the fund sits in listed shares; the rest is foreign shares, debt, money market, cash and other assets.
- Listed equity99.7%
- Rest, not itemised0.3%
Rest = foreign shares, debt, money market, cash, REIT/InvIT units and other assets.
Sectors and top 10, Oct 2026
Sector mix, Oct 2026
How the scheme's equity is spread across sectors at month end.
- 90.0%
- 7.7%
- 2.3%
AMFI's 22 sectors; one sector per stock, from the fund houses' industry labels.
Large, mid and small cap, Oct 2026
How the scheme's equity splits across large, mid and small companies, on AMFI's list.
- Small Cap40.2%
- Mid Cap30.5%
- Large Cap26.8%
- Not in AMFI's list2.4%
AMFI's list of Jun 2026.
Top 10 holdings
Its ten largest stocks, each as a share of the fund.
- 7.89%
- 5.66%
- 5.41%
- 5.25%
- 5.14%
- 4.73%
- 4.55%
- 4.28%
- 4.02%
- 3.22%
As the AMC's file prints % of NAV.
Sector weight change
Each sector's share of the fund now less a month before. It moves with prices as well as trades.
- −1.8 pts
- +1.1 pts
- +0.7 pts
Largest moves first, up to 10.
| Stock | Change | Shares before | Shares now | Difference | Change % | Value of change | Value now |
|---|---|---|---|---|---|---|---|
| NESTLEIND | New | — | 1.40 lakh | +1.40 lakh | — | +₹16.3 cr | ₹16.3 cr |
| TORNTPHARM | Added | 1.19 lakh | 1.54 lakh | +35,282 | +29.8% | +₹16.3 cr | ₹70.9 cr |
| MAXHEALTH | Added | 6.03 lakh | 7.45 lakh | +1.42 lakh | +23.5% | +₹12.2 cr | ₹64.1 cr |
| SAILIFE | Added | 2.58 lakh | 3.09 lakh | +51,372 | +19.9% | +₹8.0 cr | ₹48.2 cr |
| PGHL | Added | 74,596 | 83,211 | +8,615 | +11.5% | +₹4.9 cr | ₹47.2 cr |
| ANTHEM | Added | 4.53 lakh | 5.40 lakh | +87,486 | +19.3% | +₹7.3 cr | ₹44.8 cr |
| NATCOPHARM | Added | 2.75 lakh | 5.47 lakh | +2.72 lakh | +98.8% | +₹21.3 cr | ₹42.8 cr |
| FDC | Added | 9.97 lakh | 10.70 lakh | +72,675 | +7.3% | +₹2.7 cr | ₹40.3 cr |
| ASTERDM | Added | 3.62 lakh | 5.13 lakh | +1.51 lakh | +41.5% | +₹10.3 cr | ₹34.9 cr |
| BIOCON | Added | 2.80 lakh | 9.52 lakh | +6.72 lakh | +240.3% | +₹23.6 cr | ₹33.5 cr |
| NAVINFLUOR | Added | 21,572 | 37,188 | +15,616 | +72.4% | +₹13.6 cr | ₹32.3 cr |
| SANOFICONR | Added | 22,809 | 86,611 | +63,802 | +279.7% | +₹22.0 cr | ₹29.8 cr |
| AGARWALEYE | Added | 2.15 lakh | 3.85 lakh | +1.70 lakh | +79.0% | +₹8.7 cr | ₹19.6 cr |
| DIVISLAB | Trimmed | 92,361 | 82,875 | −9,486 | −10.3% | −₹9.3 cr | ₹81.1 cr |
| CIPLA | Trimmed | 4.74 lakh | 3.35 lakh | −1.39 lakh | −29.3% | −₹19.1 cr | ₹46.2 cr |
| ALKEM | Trimmed | 69,058 | 40,998 | −28,060 | −40.6% | −₹14.3 cr | ₹21.0 cr |
| SYMBIOTEC | Trimmed | 1.12 lakh | 58,291 | −53,968 | −48.1% | −₹6.7 cr | ₹7.3 cr |
| PIIND | Trimmed | 1.70 lakh | 33,170 | −1.36 lakh | −80.4% | −₹28.6 cr | ₹7.0 cr |
| LALPATHLAB | Trimmed | 1.34 lakh | 2,113 | −1.32 lakh | −98.4% | −₹25.2 cr | ₹0.40 cr |
| IPCALAB | Trimmed | 71,536 | 88 | −71,448 | −99.9% | −₹13.8 cr | ₹0.02 cr |
| FORTIS | Exited | 3.83 lakh | — | −3.83 lakh | — | −₹29.5 cr | ₹29.5 cr |
| MANKIND | Exited | 46,256 | — | −46,256 | — | −₹11.6 cr | ₹11.6 cr |
| JUBLPHARMA | Exited | 49 | — | −49 | — | −₹0.01 cr | ₹0.01 cr |
Value of change = the difference in shares × this month's price in the AMC's file. Value now = the whole holding's market value in that file (an exit: last month's).
Show all 40 stocksShow the first 15
Equity rows as disclosed, Oct 2026. Source: Tata Mutual Fund monthly portfolio. Report a wrong number
Large, mid and small caps, % of net assets, last 12 months
AMFI list in force each month
| Month | Large | Mid | Small | Not in AMFI's list | AMFI list |
|---|---|---|---|---|---|
| Oct 2026 | 26.8% | 30.4% | 40.2% | 2.4% | Jun 2026 |
| Sep 2026 | 26.0% | 33.9% | 37.0% | 2.9% | Jun 2026 |
| Aug 2026 | 23.3% | 36.1% | 37.3% | 2.8% | Jun 2026 |
| Jul 2026 | 23.4% | 32.0% | 42.8% | 1.0% | Jun 2026 |
| Jun 2026 | 34.0% | 24.6% | 38.8% | 0.0% | Dec 2025 |
| May 2026 | 35.2% | 23.6% | 40.6% | 0.0% | Dec 2025 |
| Apr 2026 | 35.5% | 24.1% | 40.0% | 0.0% | Dec 2025 |
| Mar 2026 | 35.8% | 24.2% | 39.6% | 0.0% | Dec 2025 |
| Feb 2026 | 36.0% | 20.8% | 40.7% | 0.0% | Dec 2025 |
| Jan 2026 | 33.6% | 24.3% | 41.2% | 0.0% | Dec 2025 |
| Dec 2025 | 36.9% | 21.8% | 38.8% | 1.2% | Jun 2025 |
| Nov 2025 | 36.5% | 19.6% | 38.8% | 0.0% | Jun 2025 |
Equity holdings' % of net assets each month, by AMFI's cap list in force that month.
Portfolio turnover, from holdings
equity only · month-end snapshots
| Month | Bought | Sold | Turnover |
|---|---|---|---|
| Oct 2026 | ₹167 cr | ₹158 cr | 10.5% |
| Sep 2026 | ₹174 cr | ₹152 cr | 9.9% |
| Aug 2026 | ₹193 cr | ₹175 cr | 11.3% |
| Jul 2026 | ₹148 cr | ₹91.2 cr | 6.2% |
| Jun 2026 | ₹95.6 cr | ₹105 cr | 6.8% |
| May 2026 | ₹94.2 cr | ₹91.6 cr | 6.8% |
| Apr 2026 | ₹32.0 cr | ₹24.1 cr | 1.9% |
| Mar 2026 | ₹108 cr | ₹68.8 cr | 5.5% |
| Feb 2026 | ₹45.3 cr | ₹71.9 cr | 3.6% |
| Jan 2026 | ₹90.9 cr | ₹84.3 cr | 6.7% |
| Dec 2025 | ₹147 cr | ₹95.3 cr | 7.4% |
| Nov 2025 | ₹167 cr | ₹211 cr | 12.9% |
The lower of bought and sold over the average equity value, from month-end holdings; it can differ from the fund house's own figure.
| Period | Return | From | To |
|---|---|---|---|
| 1 year | +11.82 % in total | 20 Nov 2025 · NAV ₹35.9776 | 20 Nov 2026 · NAV ₹40.2296 |
| 3 years | +18.74 % a year, compounded | 20 Nov 2023 · NAV ₹24.0183 | 20 Nov 2026 · NAV ₹40.2296 |
| 5 years | +16.00 % a year, compounded | 18 Nov 2021 · NAV ₹19.1325 | 20 Nov 2026 · NAV ₹40.2296 |
| Since first NAV | +13.58 % a year, compounded | 29 Dec 2015 · NAV ₹10.0351 | 20 Nov 2026 · NAV ₹40.2296 |
Past performance may not be sustained in future.
Change in the plan's NAV between the two dates shown, as AMFI publishes the NAVs (plan code 135810).
IDCW (dividend) history
0 declarations · as of 2 Nov 2026 · Source: AMFI
IDCW (formerly "dividend") declared per unit of each IDCW plan, as AMFI lists it.
Rolling returns, Tata India Pharma & Healthcare Fund - Direct Plan - Growth Option
weekly NAVs · Source: AMFI
| Window | Lowest | Median | Highest | Windows above zero |
|---|---|---|---|---|
| 1 year in total | −18.55 % 5 Aug 2016 to 11 Aug 2017 | +9.08 % 4 Jul 2025 to 10 Jul 2026 | +78.25 % 27 Mar 2020 to 1 Apr 2021 | 71 % of 510 windows ending 6 Jan 2017 to 20 Nov 2026 |
| 3 years a year, compounded | −3.20 % 1 Jan 2016 to 4 Jan 2019 | +21.08 % 3 Sep 2021 to 6 Sep 2024 | +29.90 % 20 Jul 2018 to 23 Jul 2021 | 91 % of 412 windows ending 4 Jan 2019 to 20 Nov 2026 |
| 5 years a year, compounded | +9.26 % 29 Jan 2016 to 29 Jan 2021 | +16.43 % 6 Oct 2017 to 7 Oct 2022 | +31.33 % 11 Oct 2019 to 11 Oct 2024 | 100 % of 308 windows ending 1 Jan 2021 to 20 Nov 2026 |
Past performance may not be sustained in future.
Every 1-, 3- and 5-year window ending on a week's last NAV, lowest, middle and highest.
Standard deviation of weekly NAV changes × √52. 24 Nov 2023 to 20 Nov 2026, 156 weekly changes.
Source: AMFI
High 29 Jan 2016, low 11 Aug 2017; back at the high 31 Aug 2018.
Weekly NAVs since 1 Jan 2016. Measured on each week's last NAV, so a fall within a week can be deeper than shown.
Source: AMFI
Past performance may not be sustained in future.
Next to its category: Sectoral or thematic
weekly NAVs · Source: AMFI
| Rolling window | Lower quarter | Upper quarter | Above 6 % | Above 9 % | Above 12 % | Above the category average |
|---|---|---|---|---|---|---|
| 1 year | −1.0 % | +31.2 % | 57.3 % | 50.2 % | 44.1 % | 48.0 % of 510 windows |
| 3 years | +16.6 % | +24.1 % | 84.2 % | 82.3 % | 80.1 % | 64.3 % of 412 windows |
| 5 years | +14.9 % | +23.2 % | 100.0 % | 100.0 % | 95.5 % | 62.0 % of 308 windows |
Same windows as the rolling returns above. A quarter of the windows returned less than the lower quarter, and a quarter more than the upper. "Above" columns give the share of windows. The category average is the average for windows ending the same week.
Market phases
| Phase | Dates | This scheme | Category average |
|---|---|---|---|
| Rise, 2016–18 | 26 Feb 2016 to 31 Aug 2018 a year, compounded | +2.5 % | +23.8 % 55 schemes |
| To the COVID low | 31 Aug 2018 to 27 Mar 2020 a year, compounded | −7.3 % | −17.9 % 58 schemes |
| Rise from the COVID low | 27 Mar 2020 to 27 Sep 2024 a year, compounded | +35.9 % | +37.3 % 70 schemes |
| Foreign selling, 2024–25 | 27 Sep 2024 to 28 Feb 2025 in total | −14.8 % | −19.1 % 148 schemes |
| Since March 2025 | 28 Feb 2025 to 20 Nov 2026 a year, compounded | +16.9 % | +15.6 % 165 schemes |
The phases are the site's own split of the market since 2015, measured from month end to month end.
From each quarter end to the newest NAV
| From | Dates | This scheme | Category average |
|---|---|---|---|
| From Jun 2026 | 25 Jun 2026 to 20 Nov 2026 in total | +6.6 % | +4.6 % 195 schemes |
| From Mar 2026 | 27 Mar 2026 to 20 Nov 2026 in total | +20.4 % | +18.1 % 195 schemes |
| From Dec 2025 | 26 Dec 2025 to 20 Nov 2026 in total | +13.6 % | +6.9 % 188 schemes |
| From Sep 2025 | 26 Sep 2025 to 20 Nov 2026 a year, compounded | +13.0 % | +9.0 % 182 schemes |
| From Jun 2025 | 27 Jun 2025 to 20 Nov 2026 a year, compounded | +11.0 % | +6.1 % 173 schemes |
| From Mar 2025 | 28 Mar 2025 to 20 Nov 2026 a year, compounded | +12.5 % | +11.9 % 169 schemes |
| From Dec 2024 | 27 Dec 2024 to 20 Nov 2026 a year, compounded | +5.8 % | +5.9 % 159 schemes |
| From Sep 2024 | 27 Sep 2024 to 20 Nov 2026 a year, compounded | +5.2 % | +1.6 % 148 schemes |
| From Jun 2024 | 28 Jun 2024 to 20 Nov 2026 a year, compounded | +13.0 % | +5.5 % 139 schemes |
| From Mar 2024 | 28 Mar 2024 to 20 Nov 2026 a year, compounded | +13.8 % | +9.9 % 133 schemes |
| From Dec 2023 | 29 Dec 2023 to 20 Nov 2026 a year, compounded | +16.7 % | +11.6 % 127 schemes |
| From Sep 2023 | 29 Sep 2023 to 20 Nov 2026 a year, compounded | +19.4 % | +14.6 % 118 schemes |
Root mean square of the weekly falls × √52 (rising weeks count as zero).
Its average change in the 92 weeks the category average rose, as a share of the category's.
The same for the 64 weeks the category average fell.
Past performance may not be sustained in future.
Category average = the plain average for the other schemes in the same AMFI category with the same figure (direct growth plans, each week's last NAV). It is not an index, and the scheme's place among them is not shown. Peers are today's schemes in today's category, so a scheme that has closed is not in the average, and SEBI re-sorted the categories in 2018.
Highest and lowest of 248 daily NAVs, 20 Nov 2025 to 20 Nov 2026, Tata India Pharma & Healthcare Fund - Direct Plan - Growth Option.
Source: AMFI
Calendar-year returns, Tata India Pharma & Healthcare Fund - Direct Plan - Growth Option
NAV to NAV · Source: AMFI
| Year | Return | From | To |
|---|---|---|---|
| 2025 | −3.47 % | 31 Dec 2024 · NAV ₹36.6424 | 31 Dec 2025 · NAV ₹35.3723 |
| 2024 | +42.48 % | 29 Dec 2023 · NAV ₹25.7178 | 31 Dec 2024 · NAV ₹36.6424 |
| 2023 | +38.59 % | 30 Dec 2022 · NAV ₹18.5563 | 29 Dec 2023 · NAV ₹25.7178 |
| 2022 | −6.64 % | 31 Dec 2021 · NAV ₹19.8771 | 30 Dec 2022 · NAV ₹18.5563 |
| 2021 | +20.88 % | 31 Dec 2020 · NAV ₹16.4437 | 31 Dec 2021 · NAV ₹19.8771 |
| 2020 | +66.92 % | 31 Dec 2019 · NAV ₹9.8511 | 31 Dec 2020 · NAV ₹16.4437 |
| 2019 | +7.15 % | 31 Dec 2018 · NAV ₹9.1935 | 31 Dec 2019 · NAV ₹9.8511 |
| 2018 | −0.81 % | 29 Dec 2017 · NAV ₹9.2682 | 31 Dec 2018 · NAV ₹9.1935 |
| 2017 | +6.36 % | 30 Dec 2016 · NAV ₹8.7142 | 29 Dec 2017 · NAV ₹9.2682 |
| 2016 | −13.16 % | 29 Dec 2015 · NAV ₹10.0351 | 30 Dec 2016 · NAV ₹8.7142 |
Past performance may not be sustained in future.
Change in the plan's NAV over each calendar year, last NAV to last NAV. Source: AMFI NAV files. How to read
Monthly SIP of ₹10,000, Tata India Pharma & Healthcare Fund - Direct Plan - Growth Option
XIRR · Source: AMFI
| Period | Instalments | Paid in | Value | XIRR, a year |
|---|---|---|---|---|
| 1 year 1 Dec 2025 to 2 Nov 2026 | 12 | ₹1,20,000 | ₹1,32,366 20 Nov 2026 · NAV ₹40.2296 | +20.84 % |
Past performance may not be sustained in future.
₹10,000 on the first NAV of each month, valued at the newest NAV; no stamp duty, exit load or tax taken off.
Embed this card
Copy this into any web page. The image carries its source, date and a link back; it is redrawn each night.
- Nippon India Pharma Fund49.0% overlap21 in common
- HDFC Pharma and Healthcare Fund49.0% overlap17 in common
- UTI - Healthcare Fund46.9% overlap22 in common
- Aditya Birla Sun Life Pharma and Healthcare Fund46.6% overlap23 in common
- Bandhan Healthcare Fund46.4% overlap18 in common
Overlap is the sum, over stocks both hold, of the smaller of the two weights. A measured likeness, not a suggestion to switch.
- 21 Nov 2026 · TER change: Tata India Pharma & Healthcare Fund: AMFI TER file of 21 Nov 2026: regular plan 2.40% (was 2.41%); previous file 18 Nov 2026
- 17 Nov 2026 · TER change: Tata India Pharma & Healthcare Fund: AMFI TER file of 17 Nov 2026: regular plan 2.41% (was 2.40%); previous file 15 Nov 2026
- 9 Nov 2026 · TER change: Tata India Pharma & Healthcare Fund: AMFI TER file of 9 Nov 2026: regular plan 2.40% (was 2.41%); previous file 8 Nov 2026
- 6 Nov 2026 · TER change: Tata India Pharma & Healthcare Fund: AMFI TER file of 6 Nov 2026: direct plan 1.09% (was 1.10%); previous file 5 Nov 2026
- 3 Nov 2026 · TER change: Tata India Pharma & Healthcare Fund: AMFI TER file of 3 Nov 2026: direct plan 1.10% (was 1.09%); previous file 31 Oct 2026
From AMFI's own files (scheme summary documents, NAV history, TER), as they stood on the day shown.
Questions about Tata India Pharma & Healthcare Fund
from the figures on this pageWhat are the top holdings of Tata India Pharma & Healthcare Fund?
At Oct 2026 end, Tata India Pharma & Healthcare Fund held 40 stocks (99.7% of the fund in equity). Largest: Sun Pharmaceutical Industries 7.89%, Abbott India 5.66%, Divi's Laboratories 5.41%, Healthcare Global Enterprises 5.25%, Dr. Reddy's Laboratories 5.14%; the top 10 make up 50.1%. Funds holding Sun Pharmaceutical Industries · Funds holding Abbott India · Funds holding Divi's Laboratories
What portfolio changes did Tata India Pharma & Healthcare Fund make in Oct 2026?
Compared with Sep 2026, by share count: 1 new, 12 added, 7 trimmed, 3 exited. Largest by value: Nestle India (new), Torrent Pharmaceuticals (added), Max Healthcare Institute (added), Sai Life Sciences (added).
Who manages Tata India Pharma & Healthcare Fund?
AMFI's scheme summary document names Rajat Srivastava for Tata India Pharma & Healthcare Fund (Tata Mutual Fund). Rajat Srivastava, fund manager portfolio
All schemes of Tata Mutual Fund →
Mutual fund investments are subject to market risks; read all scheme related documents carefully.